MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
IMUX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Immunic (IMUX) Earnings Date & Reports

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

A.I. Advisor
published Earnings

IMUX is expected to report earnings to fall 23.35% to -15 cents per share on November 06

Immunic IMUX Stock Earnings Reports
Q3'25
Est.
$-0.15
Q2'25
Missed
by $0.03
Q1'25
Missed
by $0.03
Q4'24
Missed
by $0.01
Q3'24
Missed
by $0.02
The last earnings report on August 07 showed earnings per share of -20 cents, missing the estimate of -17 cents. With 685.74K shares outstanding, the current market capitalization sits at 85.83M.
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
IMUX
TickeronSetup
Buy or SellView
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View Trends For IMUX
(Try 14 days for Free)
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMUX showed earnings on August 07, 2025. You can read more about the earnings report here.
View AI-Driven Trading
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com